Biomedical Sciences

Quillen College of Medicine

Qian Xie

Qian Xie

Associate Professor

 

Additional Contact Information: 


Department of BioMedical Sciences
Quillen College of Medicine 
Stanton-Gerber Hall, Bldg.178 
P.O. Box 70582 
Office A026, Lab A021-022 
Phone: 423-439-5332 
Email: xieq01@etsu.edu

EDUCATION/PROFESSIONAL EXPERIENCE

Postdoctoral Fellow,2006 Molecular Oncology, Van Andel Institute, Grand Rapids, MI, US

Ph.D., 2002 Fudan University Zhongshan Hospital, Shanghai, China. 

M.D., 1995 Fudan University Shanghai Medical College, Shanghai, China.

2021 - Present - Associate Professor, Department of Biomedical Sciences, East Tennessee State University, Johnson City, TN

2016- 2021 - Assistant Professor, Department of Biomedical Sciences, East Tennessee State University, Johnson City, TN

2013-2015 - Research Assistant Professor, Van Andel Research Institute, Grand Rapids, MI

2010-2013 - Senior Research Scientist, Van Andel Research Institute, Grand Rapids, MI

2006-2010 - Research Scientist, Van Andel Research Institute, Grand Rapids, MI   

RESEARCH/TEACHING INTERESTS

The success of molecular targeted therapy in cancer depends on knowledge of essential pathways that contribute to oncogenesis and the molecular targets that control pathway activity. The major research interest of my lab is to understand the role of MET signaling pathway in cancer, with primary focus on glioblastoma and hepatocellular carcinoma. We use both in vitro cell based assays and in vivo animal models to understand the molecular regulation of MET and Tyrosine Kinase signaling pathways in order to develop therapeutic strategies for cancer treatment. 

Research Projects:

  1. To determine the molecular mechanisms of MET-targeted therapy and the therapeutic combination strategies.
  2. To develop MET-targeting T cell therapy in hepatocellular carcinoma and glioblastoma
  3. To establish preclinical animal modeling systems for studying tumor biology and therapeutics in glioblastoma.



SELECTED PUBLICATIONS

  1. Qin A, Musket A, Musich PR, Schweitzer JB, Xie Q. Receptor tyrosine kinases as druggable targets in glioblastoma: Do signaling pathways matters?
  2. Land CA, Musich PR, Haydar D, Krenciute G, Xie Q. Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Charging the T Cells to Fight J Transl Med 18: 428, 2020
  3. Qin Y, Musket A*, Kou J, Preiszner J, Tschida BR, Qin A, Land CA,  Staal B, Kang L, Tanner K, Jiang Y, Schweitzer JB, Largaespada, DL, and Xie Q. Overexpression of HGF/MET Axis along with p53 Inhibition Induces de novo Glioma Formation in Mice. Neuro-Oncology Advance. In press. 2020
  4. Kou J, Musich PR, Staal B, Kang L, Qin Y, Yao ZQ, Zhang B, Wu W, Tam A, Huang A, Hao HX, Vande Woude GF, Xie Q. Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody. J Transl Med. 12;16(1):253, 2018. 
  5. Li S, Johnson J, Peck A, and Xie Q. Near infrared fluorescent imaging of brain tumor with IR780 dye incorporated phospholipid nanoparticles. J Transl Med. 15(1):18, 2017
  6. Johnson J, Ascierto ML, Kang L, Bradley R, Mittal S, Briggs M, Tanner K, Berens ME, Marincola FM, Vande Woude GF, and Xie Q. Identifying HGF signature for MET-targeted therapy in glioblastoma. J Transl Med. 13:306, 2015
  7. Xie Q*, Mittal S, Berens ME. Targeting adaptive glioblastoma: an overview of proliferation and invasion. Neuro-Oncology. 16;12:1575-1584, 2014 [*Corresponding author]
  8.  Xie Q*, Su Y, Dykema K, Johnson J, Koeman J, De Giorgi V, Huang A, Schlegel R, Essenburg C, Kang L, Iwaya K, Seki S, Khoo SK, Zhang B, Buonaguro FM, Marincola FM, Furge K, Vande Woude GF, and Shinomiya N*. Overexpression of HGF promotes HBV-Induced hepatocellular carcinoma progression and is an effective biomarker for Met-targeting therapy. Genes & Cancer, 4:247-60, 2013 [* Co- corresponding authors] Highlighted as Cover Story of the July/August issue
  9. Xie Q*, Bradley R, Koeman J, Worschech A, Kang L, Su Y, Kefene L, Essenburg C, Kaufman D, DeKoning T, Enter M, O’Rourke TJ, Marincola FM, Vande Woude GF*. HGF-autocrine activation in glioblastoma predicts the sensitivity to MET inhibition in glioblastoma. Proc Natl Acad Sci U S A. 10;109(2):570-5, 2012 [* Co-corresponding authors]
     
    Textbook
  10. Shinomiya N, Kataoka H, Xie Q. Regulation of signal transduction in human cell research. Singapore: Springer Nature; 2018

    Book Chapters
  11. Thewke D, Kou J, Fulmer M, Xie Q. The HGF/MET signaling and therapeutics in cancer. In: Regulation of signal transduction in human cell research. edn. Edited by Shinomiya N, Kataoka H, Xie Q. Singapore: Springer Nature; 2018: 155-182
  12. Shinomiya N, Xie Q, Vande Woude G: Met activation and carcinogenesis. In: Regulation of signal transduction in human cell research. edn. Edited by Shinomiya N, Kataoka H, Xie Q. Singapore Springer Nature 2018: 129-154